Last reviewed · How we verify
SSRI; SNRI; TCA
SSRI; SNRI; TCA is a Small molecule drug developed by Tirat Carmel Mental Health Center. It is currently in Phase 1 development. Also known as: paroxetine, fluoxetine, sertraline, escitalopram, citalopram, mirtrazapine, venlafaxine, anafranil.
SSRIs, SNRIs, and TCAs are types of antidepressants used to treat Major Depressive Disorder, as indicated by ClinicalTrials.gov. These medications work through different mechanisms, with SSRIs and SNRIs primarily affecting serotonin levels, and TCAs affecting both serotonin and norepinephrine levels, according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SSRI; SNRI; TCA |
|---|---|
| Also known as | paroxetine, fluoxetine, sertraline, escitalopram, citalopram, mirtrazapine, venlafaxine, anafranil |
| Sponsor | Tirat Carmel Mental Health Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Discontination of Antidepressants in Remitted Depression (PHASE4)
- Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
- Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder (PHASE4)
- Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSRI; SNRI; TCA CI brief — competitive landscape report
- SSRI; SNRI; TCA updates RSS · CI watch RSS
- Tirat Carmel Mental Health Center portfolio CI
Frequently asked questions about SSRI; SNRI; TCA
What is SSRI; SNRI; TCA?
Who makes SSRI; SNRI; TCA?
Is SSRI; SNRI; TCA also known as anything else?
What development phase is SSRI; SNRI; TCA in?
Related
- Manufacturer: Tirat Carmel Mental Health Center — full pipeline
- Also known as: paroxetine, fluoxetine, sertraline, escitalopram, citalopram, mirtrazapine, venlafaxine, anafranil
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing